Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Enanta Pharmaceuticals will present Phase 2 data for zelicapavir, its oral once-daily N-protein inhibitor for RSV, at IDWeek 2026 on October 22 in Washington, DC. The poster covers a global, randomized, placebo-controlled Phase 2 trial in high-risk adults, reporting decreases in time to symptom resolution, hospitalization, and viral load.
Key figures
- Drug Name
- zelicapavir
- Phase Of Trial
- Phase 2
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.